Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls

Lung Cancer

Volumn 17, Issue 1, 1997, Pages 61-68

  Shaw, Gail L ^a   Weiffenbach, Barbara ^b   Falk, Roni T ^c   Frame, James N ^d   Issaq, Haleem J ^e   Moir, Donald T ^b   Caporaso, Neil ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b GENOME THERAPEUTICS CORPORATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e SAIC FREDERICK INC   (United States)

Author keywords

debrisoquine; genetic susceptibility; lung cancer

Indexed keywords

4 HYDROXYDEBRISOQUINE; DEBRISOQUINE; DRUG METABOLIZING ENZYME;

ARTICLE; CANCER PATIENT; CANCER RISK; CAUCASIAN; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG METABOLISM; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; NORTH AMERICA; PHENOTYPE; PRIORITY JOURNAL;

ALLELES; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LUNG NEOPLASMS; MALE; NORTH AMERICA; PHENOTYPE; PREGNANCY; VARIATION (GENETICS);

EID: 0030909631     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00649-1     Document Type: Article

References (16)

1. Agú;ndez JAG, Martinez C, Ladero JM, Ledesma MC, Ramos JM, Martin R, Rodriguez A, Jara C, Benitez J. Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994; 55: 10-14.
2. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993; 3: 123-130.
3. Fox SD, Shaw GL, Caporaso NE, Welsh SE, Mellini DW, Falk RT, Issaq HJ. The determination of debrisoquine and its 4-hydroxy metabolite in urine by capillary gas chromatography and high performance liquid chromatography. J Liq Chromatogr 1993; 16: 1315-1327.
4. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48: 943-950.
5. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquine-sparteine polymorphism. Clin Pharmacol Ther 1991; 50: 233-238.
6. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (London) 1990; 347: 773-776.
7. Graf T, Broly F, Hoffman F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992; 43: 399-403.
8. Haliassos A, Chomel JC, Tesson L, Baudis M, Kruh J, Kaplan JC, Kitzis A. Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res 1989; 17: 3606.
9. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
10. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3: 19-27.
11. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990; 265: 17209-17214.
12. Kumar R, Dunn LL. Designed diagnostic restriction fragment length polymorphisms for the detection of point mutations in ras oncogenes. Oncogene Res 1989;4:235-241.
13. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 1991; 247: 267-281.
14. Shaw GL, Falk RT, Deslauriers J, Frame JN, Nesbitt JC. Pass HI, Issaq HJ, Hoover RN, Tucker MA. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995; 4: 41-48.
15. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1: 26-32.
16. Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13: 1035-1038.